PureTech Health (PRTC) said Thursday the US Food and Drug Administration has given fast track designation to LYT-200 to treat acute myeloid leukemia.
The label was designed to expedite the assessment of drugs for serious diseases with unmet medical need, the company said.
The regulator previously granted orphan drug designation to LYT-200 to treat acute myeloid leukemia, as well as a separate fast track designation to treat head and neck cancers, the company said.
Price: 17.55, Change: -0.76, Percent Change: -4.15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments